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Abstract
Endocannabinoids regulate energy balance and lipid metabolism by stimulating the cannabinoid receptor type 1 (CB1).
Genetic deletion and pharmacological antagonism have shown that CB1 signaling is necessary for the development of
obesity and related metabolic disturbances. However, the sufficiency of endogenously produced endocannabinoids to
cause hepatic lipid accumulation and insulin resistance, independent of food intake, has not been demonstrated. Here, we
show that a single administration of isopropyl dodecylfluorophosphonate (IDFP), perhaps the most potent pharmacological
inhibitor of endocannabinoid degradation, increases hepatic triglycerides (TG) and induces insulin resistance in mice. These
effects involve increased CB1 signaling, as they are mitigated by pre-administration of a CB1 antagonist (AM251) and in CB1
knockout mice. Despite the strong physiological effects of CB1 on hepatic lipid and glucose metabolism, little is known
about the downstream targets responsible for these effects. To elucidate transcriptional targets of CB1 signaling, we
performed microarrays on hepatic RNA isolated from DMSO (control), IDFP and AM251/IDFP-treated mice. The gene for the
secreted glycoprotein lipocalin 2 (lcn2), which has been implicated in obesity and insulin resistance, was among those most
responsive to alterations in CB1 signaling. The expression pattern of IDFP mice segregated from DMSO mice in hierarchal
cluster analysis and AM251 pre-administration reduced (.50%) the majority (303 of 533) of the IDFP induced alterations.
Pathway analysis revealed that IDFP altered expression of genes involved in lipid, fatty acid and steroid metabolism, the
acute phase response, and amino acid metabolism in a CB1-dependent manner. PCR confirmed array results of key target
genes in multiple independent experiments. Overall, we show that acute IDFP treatment induces hepatic TG accumulation
and insulin resistance, at least in part through the CB1 receptor, and identify novel cannabinoid responsive genes.
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Introduction
Obesity elicits a cluster of interrelated disorders, termed the
‘‘metabolic syndrome’’, that increase the risk of cardiovascular
disease [1]. Dysregulation of the endocannabinoid (EC) system has
been linked to increased adiposity in humans by epidemiological
and genetic data [2,3,4]. Obesity and hyperglycemia are
associated with elevated plasma and tissue endocannabinoid levels
in animal models and obese patients [2,5,6,7]. In four large human
trials, 20 mg/day of the cannabinoid type 1 receptor (CB1)
antagonist rimonabant resulted in clinically significant and
prolonged reductions in body weight, waist circumference, and
components of the metabolic syndrome [8,9,10,11]. The effects of
rimonabant on plasma lipids and glycosylated hemoglobin appear
to be partly independent of weight loss [12]. Pharmacological or
genetic ablation of CB1 in diet-induced and genetic mouse models
of obesity results in a transient hypophagic response, followed by
prolonged effects on weight loss, adiposity, and normalization of
metabolic parameters [13,14,15,16,17,18]. These effects suggest
that reduced food intake does not fully explain the improvement in
adiposity-related measures with CB1 inactivation. Hepatic CB1
activation increases de novo lipogenesis through SREBP1c activa-
tion, and decreases fatty acid oxidation by inhibiting AMP kinase
[19,20]. Furthermore, hepatocyte specific deletion of CB1 or
administration of a non-brain-penetrant CB1 antagonist prevents
hepatic steatosis, hyperlipidemia, and insulin resistance on a high-
fat diet, independent of weight gain [21,22]. Similarly, ethanol-
induced hepatic steatosis is absent in hepatocyte specific CB1 2/
2 animals [20]. Together these observations raise the possibility
that aberrant EC signaling mediates development of the metabolic
syndrome, both by influencing body weight and directly regulating
metabolic processes.
While the necessity of CB1 signaling for development of obesity
and related metabolic disturbances has been demonstrated, it is
uncertain if EC elevation is sufficient to induce changes in hepatic
lipid and glucose metabolism independent of changes in food
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underlying the powerful regulatory effects of CB1 on hepatic
metabolism remain largely unclear. In the present study, we
investigate the effects of elevated ECs on hepatic lipid content and
insulin sensitivity independent of food intake. The ECs responsible
for CB1 signaling are N-arachidonyl ethanolamine (AEA, or
anandamide) and 2-arachidonoyl glycerol (2-AG). Both are
arachidonic acid derivatives produced locally by phospholipases,
N-acyl-phosphatidylethanolamine-selective phospholipase D, and
sn-1-selective diacylglycerol lipases, respectively [23]. Anandamide
is a partial CB1 agonist with moderate affinity, and 2-AG is a
lower affinity complete CB1 agonist that is present at much higher
concentrations than AEA. Signaling is terminated by enzymatic
breakdown of AEA and 2-AG by fatty acid amide hydrolase
(FAAH) and monoacylglycerol lipase (MAGL), respectively [23].
Since exogenously administered 2-AG and AEA are rapidly
degraded [24], we have chosen to induce increases in their levels
by inhibiting the enzymes responsible for their degradation. The
organophosphorus (OP) compound isopropyl dodecylfluoropho-
sphonate (IDFP) inhibits both MAGL and FAAH and raises 2-AG
and anandamide levels in vivo [25,26]. We have previously shown
that IDFP increases circulating triglyceride (TG) concentrations in
a CB1-dependent manner through the decreased clearance of TG-
rich lipoproteins [26]. CB1 antagonists and knockout mice can be
used to assess the contribution of CB1 signaling to IDFP effects.
We describe here the CB1-dependent effects of IDFP on hepatic
lipid content and insulin sensitivity. In addition, to gain
mechanistic insight into CB1 regulation of lipid and glucose
metabolism, we assayed global hepatic gene expression by
microarray analysis of IDFP and AM251/IDFP-treated mice
(Fig. 1).
Materials and Methods
Chemicals
AM251, the 4-iodophenyl analog of rimonabant that has a 4-
chlorophenyl substituent, was obtained from Tocris Cookson Inc.
IDFP was synthesized as previously described [27].
Animals
This study was carried out in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The protocol was approved by
the University of California-Berkeley Animal Care and Use
Committee (Protocol R071-0310R). Injection of test compounds
was performed under isoflurane anesthesia, and all efforts were
made to minimize suffering. Swiss Webster mice were from
Harlan Laboratories. CB1 +/+ and 2/2 breeding pairs were
obtained from Andreas Zimmer and Carl Lupica [25,28]. All
experiments used Swiss Webster mice unless specifically stated
otherwise, i.e. CB1 +/+ or 2/2. All mice were 6–8 weeks of age,
male, and weighed 18–23 g. Mice were fasted for 4 h, treated i.p.
at 1 ml/g with dimethyl sulfoxide (DMSO) or test compounds
dissolved in DMSO, and sacrificed 4 h after treatment with livers
flash frozen. IDFP-treated mice in this study displayed cannabi-
noid-mediated behavioral effects similar to those previously
reported [25].
Biochemical Analyses
Flash frozen liver samples were homogenized in radioimmuno-
precipitation assay buffer and TG and cholesterol were analyzed
by enzymatic end-point measurements utilizing enzyme reagent
kits (Catalog # F6428 & T2449, Sigma). Protein concentration of
the hepatic homogenate was determined by the bicinchoninic acid
method.
Microarray Analysis
RNA was isolated from homogenized liver using the RNAeasy
kit (Qiagen) and cRNA was synthesized from isolated RNA using
the Illumina TotalPrep RNA amplification kit (Applied Biosys-
tems). cRNAs from 19 individual mice were hybridized to
mouseref-8 v2.0 beadchips and read on the iscan instrument.
Group data represent the average of 5–8 individual mice
randomized to three chips. Data were processed using BeadStudio
software 3.2 (Illumina) with quantile normalization, background
subtraction, and multiple testing correction (Benjamini and
Hochberg false discovery rate). To quantify the effects of
AM251 pre-administration relative to IDFP induced alterations
a reversal metric was calculated as follows, with DMSO fold as
1.00:
reversal~ 1  ð DMSO fold AM251=IDFP fold ðÞ ð
= DMSO fold IDFP fold ð ÞÞÞ|100:
For example, lipocalin 2 (lcn2) has fold changes of 1.00 (DMSO),
0.20 (IDFP), and 2.68 (AM251/IDFP), thus percent reversal=
(1–((1.00–2.68)/(1.002.20)))6100=310%.
The web-based data analysis tools Panther (http://www.
pantherdb.org) and FUNCASSOCIATE 2.0 ((http://llama.med.
harvard.edu/funcassociate) were used with default settings. All
microarray data is MAIME compliant and has been deposited in
the GEO database (accession # GSE22949).
PCR Confirmation
Relative quantitative PCR was performed on the ABI7900
system using SYBR green master mix in triplicate (Applied
Biosystems). All genes were normalized to an endogenous control
gene, gusb. The primers used are given in Supplemental Table S1.
Glucose Tolerance and Insulin Sensitivity
Glucose (2 g/kg) was administered i.p. 2 h following treatment
with IDFP or DMSO. Blood glucose was determined by the
Onetouch ultra monitor system (Lifescan, Inc.) 0, 15, 30, 60, 90,
120 and 180 min following glucose administration. Plasma insulin
was determined by ELISA (Millipore) 0, 10, 15, and 30 min
following glucose administration. To test insulin sensitivity, insulin
(0.5 U/kg) was administered i.p. 2 h following treatment with
IDFP or DMSO and glucose was determined as above at 0, 15, 30,
and 60 min following treatment.
Figure 1. Effects of IDFP and AM251 on gene expression and
physiological outcomes.
doi:10.1371/journal.pone.0026415.g001
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Results are presented as mean 6 standard error. One- and two-
way repeated measures analysis of variance was used to test
significance of treatment effects. Post-hoc analysis (Tukey’s)
examined significance (p,0.05) of individual treatment effects.
All analyses were performed using JMP version 7.0. Additional
statistical information is given in Supplemental Table S2.
Results
1.1 IDFP produces CB1-dependent hepatic steatosis
To test the effects of elevated ECs on hepatic lipid levels, mice
were treated with IDFP or vehicle control (DMSO). To determine
the CB1-dependence of these effects, a subset of the IDFP group
was pretreated with the CB1 antagonist, AM251. IDFP treatment
significantly increased hepatic TG levels (Fig. 2A), while AM251
pre-administration partially reversed this effect (Fig. 2A). IDFP
had no significant effect on hepatic cholesterol content (Fig. 2B).
The partially CB1-dependent increase in hepatic TG but not
cholesterol levels was confirmed in CB1 2/2 mice and wild-type
littermates treated with IDFP (Supplemental Fig. S1). These effects
of cannabinoid signaling on hepatic triglyceride levels are
consistent with previous studies showing cannabinoid agonists
increase de novo lipogenesis and lipid accumulation in the liver
[29,30].
1.2 IDFP impairs glucose tolerance by both CB1-
dependent and -independent effects
To test the effect of MAGL/FAAH inhibition on glucose
homeostasis, mice were treated with DMSO or IDFP with or
without pre-administration of AM251 and then subjected to a
glucose tolerance test. IDFP produced profound glucose intoler-
ance (Fig. 3A). As the glucometer used in these studies had a
maximum reading of 600 mg/dl, the glycemia of IDFP-treated
animals may be underestimated, although 4 h after glucose
administration the glucose levels of all animals were in the
quantifiable range (data not shown). The IDFP effect was
mitigated, but not completely reversed, by pre-administration of
AM251 (Fig. 3A). Likewise, IDFP induced severe glucose
intolerance in wild-type C57BL6 mice, but CB1 2/2 littermates
were less susceptible to IDFP induced glucose intolerance
(Supplemental Fig. S2). Unexpectedly, the CB1 2/2 mice were
more glucose intolerant than their wild-type littermates. To test if
the glucose intolerance resulted from insulin resistance or altered
insulin secretion, insulin levels were determined 10,15, and 30 min
after glucose administration in DMSO and IDFP-treated Swiss
Webster mice. IDFP-treated mice had significantly elevated levels
of insulin at all time points (10 min: 0.6860.07 vs. 1.1960.09 ng/
ml, 15 min: 0.4460.09 vs 1.2960.26 ng/ml; 30 min: 0.4260.03
vs 0.736.08 ng/ml, all p,0.05, n=5). As the elevated insulin
levels suggest insulin resistance, an insulin tolerance test was
performed to determine the effects of IDFP on insulin resistance.
Although the effects did not reach statistical significance, IDFP
decreased, while AM251 pretreatment partially restored, the
glucose-lowering efficacy of insulin (Fig. 3B).
1.3 IDFP Alters Hepatic Gene Expression
1.3.1 Cluster Analysis. To identify the pathways activated
by IDFP administration, specifically those dependent on CB1
activation, microarray analysis was performed on hepatic mRNA
from DMSO, IDFP and AM251/IDFP-treated animals. Of the
18,097 genes present on the array, 8,857 were detected in at least
one of the groups at p,0.05. IDFP-treated animals segregated
well from DMSO treated animals in cluster analysis, while results
for the AM251/IDFP-treated animals were intermingled with
those for the DMSO treated animals (Fig. 4). After correction for
multiple testing, the expression of 533 genes was significantly
altered by IDFP administration (Supplemental Table S3). Of
these, 230 were increased by IDFP, while 303 were decreased.
These 533 genes had a skewed distribution of p-values for the
IDFP vs. AM251/IDFP comparison, making them inappropriate
for the generation of q-values and false discovery rate analysis. To
quantitate the ability of AM251 pre-administration to reverse
IDFP-induced changes in gene expression, the percent reversal of
the 533 significantly altered genes was determined (see methods
for calculations). Although there was a large range (2128 to
310%), the average percent reversal (5862%) was high, indicating
that AM251 reversed a significant portion of the IDFP effects on
gene expression. Lipocalin 2 (lcn2) had the highest percent reversal
(310%), with IDFP decreasing and AM251 pre-administration
increasing expression levels, effects confirmed by PCR (Fig. 5).
1.3.2 Identification of Functional Categories. Two
complementary approaches were used to identify functional
categories within the data set. First, the Panther classification
system was used to determine biological processes regulated within
the dataset. This analysis accounts for the fold change of every
Figure 2. CB1-dependent effects of IDFP on hepatic TG (A) and
cholesterol (B) levels. Mice were treated with DMSO or IDFP (10 mg/
kg, ip, 4 h) alone or 15 min following AM251 (10 mg/kg, ip). n=20–21.
Groups not sharing a common superscript letter are significantly
different (p,0.05).
doi:10.1371/journal.pone.0026415.g002
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at a time. Lipid, fatty acid, and steroid metabolism was the only
category identified when IDFP was compared with both DMSO
and AM251/IDFP (Supplemental Table S4). To identify a subset
of genes with significantly altered CB1-dependent expression,
upregulated (n=112) and downregulated (n=168) genes with
.50% reversal and a nominal p value ,0.05 between the IDFP
and IDFP/AM251 groups were queried in Funcassociate 2.0.
Although the 50% reversal cutoff for inclusion of a gene as CB1-
dependent was arbitrary, stricter thresholds (80% cutoff) yielded
similar results in the pathway analysis. While the upregulated
genes were not significantly enriched for any gene ontology
attributes, the downregulated genes were enriched in genes with
roles in translation, cellular amino acid metabolic processes, and
the acute phase response (Supplemental Table S5). The altered
CB1-dependent genes represented within the enriched pathways
and biological processes are shown in Table 1.
1.3.3 PCR Confirmation. To confirm the effects of IDFP on
hepatic gene expression, quantitative PCR was performed on a
larger set of samples representing three independent experiments,
including the one used for the array data. The results confirmed
increased expression of several key components of the lipid and
cholesterol metabolism gene set including ldlr, insig1, pgc1b,
lpin2, and acsl1 (Fig. 6A). With the exception of lpin2, the CB1-
dependence of these effects was shown by their reversal by
AM251. Given the effects of IDFP on the SREBP2 target genes,
insig1 and ldlr, we also chose to probe the effect of IDFP on
expression of hmgcr which encodes the rate-limiting enzyme in
cholesterol biosynthesis, HMGCoA reductase, and which was not
represented on the array. IDFP increased expression of hmgcr, an
effect that was completely prevented by AM251 pre-
administration (Fig. 6A).
The PCR results confirmed CB1-dependent inhibitory effects of
IDFP on several acute phase (saa2, orm2, stat3) and amino acid
response genes (asns, aars, eef1e1, psat1, rars) (Fig. 6B,C). As stat3
is an essential transcription factor involved in the acute phase
response, we tested the effect of IDFP on the canonical stat3
downstream targets apcs and lbp [31]. IDFP decreased expression
of both apcs and lbp in a CB1-dependent manner. There was a
strong correlation between the array and PCR data for all genes
tested (r=0.7–1.0). The effects of IDFP on expression of genes
involved in lipid metabolism and stat3 signaling were determined
in CB1 2/2 and wildtype littermates. There was a significant
genotype-treatment interaction for several of the lipid metabolism
Figure 3. IDFP causes CB1-dependent and -independent
glucose intolerance (A) and insulin resistance (B). Mice were
treated with DMSO or IDFP (10 mg/kg, i.p., 4 h) alone or 15 min
following AM251 (10 mg/kg, i.p.). Two h following DMSO or IDFP
treatment, mice were administered glucose (2 g/kg) or insulin (0.5 U/
kg) and plasma glucose was determined at the time points indicated.
n=4–5. Results were analyzed by repeated measures analysis of
variance. The three groups responded in a significantly different fashion
to glucose (F=34.50, p=,0.0001), but not insulin (F=1.96, p=.137).
doi:10.1371/journal.pone.0026415.g003
Figure 4. Hierarchical clustering of the transcriptome of
individual mice. Dendrogram representation of cluster analysis from
BeadStudio software 3.2 (Illumina).
doi:10.1371/journal.pone.0026415.g004
Figure 5. CB1-dependent effects of IDFP on hepatic expression
of lipocalin 2. RNA was isolated from the mice used for the
experiment in Fig. 2. Array n=5–8. PCR n=17–18. Groups within the
array and PCR assays not sharing a common superscript letter are
significantly different (p,0.05).
doi:10.1371/journal.pone.0026415.g005
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dependent effect of IDFP (Supplemental Table S6). Stat3 and its
targets, lbp and apcs, displayed the expected trend, but the results
did not reach statistical significance (Supplemental Table S6).
Discussion
The data presented here establish that IDFP induces hepatic
steatosis and insulin resistance partially through CB1 signaling.
IDFP significantly increased hepatic TG levels 4 h after treatment.
This effect was largely mediated by the CB1 receptor, as it
was mitigated by AM251 pre-administration and deficient in CB1
2/2 mice. As neither the effects of AM251 nor the genetic
absence of CB1 in the animals used in the current study are
confined to the periphery, the site of CB1 action responsible for
the observed effects cannot be addressed. However, all animals
were fasted prior to and during the experimental period
eliminating differential energy intake as a confounding variable.
Hepatic TG content reflects the balance of secretion, uptake,
synthesis, and oxidation. We have previously shown that IDFP
decreases clearance of circulating TGs with no effect on hepatic
TG secretion [26]. The IDFP-induced increase in hepatic TG
content combined with a lack of effect on TG secretion suggests
that CB1 stimulation may favor TG storage over secretion.
Correspondingly, treatment with a non-brain-penetrant CB1
antagonist has been reported to reduce hepatic steatosis and
increase secretion of TG-rich lipoproteins [22]. Since CB1
antagonists increase adipose TG lipolysis, CB1 stimulated hepatic
TG accumulation likely does not result from increased delivery of
FA from adipose tissue [16,32]. Hepatic CB1 stimulates sprebp1c
and inhibits AMP kinase making both decreased oxidation and
increased synthesis of fatty acids likely contributors to the IDFP
induced increase in hepatic TG content [20,21]. Indeed, we found
that IDFP increases expression of the lipogenic genes, fas and
srebp1c, in a CB1-dependent manner [26]. The CB1 independent
effects of IDFP on hepatic TGs may result in part from lipolytic
defects resulting from MAGL blockade [33], other monoacylgly-
cerol or N-acylethanolamine or N-acyltaurine substrates of MAGL
and FAAH [34,35], respectively, or off-target effects of IDFP [25].
Further studies with specific MAG lipase inhibitors and knockout
mice will be necessary to clarify the role of MAG lipase in the
lipolytic cascade.
We have shown that IDFP causes profound glucose intolerance.
Our results are consistent with previous reports that synthetic CB1
agonists caused glucose intolerance and insulin resistance in wild-
type but not in hepatocyte-specific CB1 knockout mice [21].
Conversely, genetic or pharmacological inactivation of CB1
prevents diet-induced alterations in glucose and insulin tolerance
[21]. In humans, D
9-tetrahydrocannabinol (THC) has been shown
to cause glucose intolerance [36]. Although a CB1-dependent
effect of IDFP on glucose intolerance is indicated by our finding
that this was substantially prevented by AM251, there were also
CB1-independent effects of IDFP. Similarly, CB1 knockout mice
were less susceptible to IDFP induced glucose intolerance, but still
had a significant response.
Glucose tolerance reflects the ability of insulin to drive glucose
uptake and shut down glucose production. In the present study, the
elevated insulin levels in IDFP-treated animals following glucose
administration indicate that the glucose intolerance likely results
from severe insulin resistance. Glucose response during an insulin
tolerance test largely represents the ability of insulin to inhibit
glucose production in the liver. Our results suggest that although
some reduction of hepatic insulin sensitivity may have been induced
by IDFP, this is likely not sufficient to have produced the profound
glucose intolerance that was observed. There may also be effects of
ECs on peripheral glucose uptake. CB1 antagonist administration
increases muscle glucose uptake muscle in ob/ob mice [37]. EC
levels have also been shown to be higher in the muscle of diet-
induced obese mice [5]. Physical inactivity in IDFP-treated mice
may also contribute indirectly to reduced glucose utilization [25].
Although we did not observe changes in resting glucose levels, this
may be due to the acute nature of the IDFP treatment regimen used
in this study. Whether chronic EC elevation leads to fasting
hyperglycemia warrants further investigation.
The CB1-independent effects of IDFP on glucose tolerance are
shared by other OP compounds [38]. Instances of OP poisoning
Table 1. Altered CB1-dependent Genes Represented within
the Enriched Pathways.
Pathway
Fold Change vs.
DMSO
a (1.00)
Reversal by
AM251
b (%)
IDFP AM251/IDFP
Acute Phase Response
orm1 0.70 1.43 246
orm2 0.41 1.79 233
saa2 0.25 1.30 139
saa4 0.51 1.11 123
stat3 0.52 1.01 102
Amino Acid Metabolism
& Translation
Rars 0.74 1.12 147
Lars 0.63 1.11 129
Aars 0.65 1.00 100
Iars 0.65 0.97 93
Farsb 0.74 0.96 84
rars2 0.62 0.87 66
Gars 0.65 0.85 58
ncoa5 0.57 0.81 55
eef1e1 0.57 1.14 133
eif2b4 0.73 0.95 82
psat1 0.29 0.85 79
Pelo 0.64 0.91 75
Asns 0.15 0.68 62
eif2ak2 0.51 0.80 59
Lipid, Fatty Acid, and
Steroid Metabolism
sgms2 2.00 0.60 140
pgc1b 6.78 2.16 80
pla2g6 1.68 1.30 55
mtmr3 2.08 1.42 61
lpin2 3.22 1.70 69
insig1 1.90 1.08 91
chkb 1.81 1.26 67
apol9b 1.66 1.02 97
acsl1 1.79 1.05 93
ldlr 4.50 1.30 92
aAverage fold change for 5 (DMSO), 8 (IDFP), and 7 (AM251/IDFP) individual
mice.
bSee methods for calculation of reversal by Am251.
doi:10.1371/journal.pone.0026415.t001
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and diabetic ketosis [39,40,41]. Acetylcholinesterase (AChE)
inhibition has been proposed to underlie OP-induced hypergly-
cemia [42]. However, since IDFP does not inhibit AChE in vivo,
IDFP, and perhaps other OPs, produce glucose intolerance via
CB1 and AChE independent pathways.
Our findings suggest that increased CB1 signaling can be
considered a cause rather than a consequence of hepatic steatosis
and insulin resistance. As only a few genes have been identified as
CB1 responsive in the liver, we aimed to identify novel CB1 targets
stimulated by endocannabinoids. Although the microarrays
detected ,9000 genes in at least one of the sample groups,
certain genes were not represented on the chip, such as hmgcr.
PCR was used to validate several of the array findings in multiple
independent experiments.
Hepatic CB1 has been shown to increase expression of the
lipogenic genes fas, acc, and srebp1c [30]. Here we identify pgc1b
as a novel downstream target of CB1. This is of particular interest
as PGC1b is a co-activator for SREBP1c and is necessary for the
development of diet-induced hyperlipidemia [43]. Likewise
expression of acsl1 was stimulated by CB1 activation. Acyl-CoA
synthetases activate fatty acids into acyl-CoAs, providing sub-
strates for downstream fatty acid metabolic processing, such as
esterification and beta-oxidation. Acsl1 is highly expressed in the
liver and hepatocyte specific loss of acsl1 has been shown to
decrease both fatty acid oxidation and incorporation into TG [44].
Acsl1 overexpression enhances incorporation of fatty acids in
diacylglycerol, but does not cause TG accumulation [45]. The
effect of raising pgc1b and acsl1 expression in the setting of CB1
signaling requires further study.
Several of the key regulators of cholesterol homeostasis were
increased by IDFP in a CB1-dependent manner. This is of
particular interest as CB1 signaling regulates plasma lipid and
lipoprotein metabolism. In clinical trials, rimonabant had greater
effects on TG and HDL cholesterol than would be expected based
on weight loss alone [12]. Hepatocyte specific CB1 2/2 mice are
immune to diet induced alterations in plasma lipoproteins and we
have previously shown that IDFP causes hypertriglyceridemia
secondary to decreased clearance of TG rich lipoproteins [21,26].
The coordinated regulation of several SREBP2 target genes by
IDFP in a CB1-dependent manner may result from direct
regulation of this pathway by the CB1 signaling cascade.
Alternatively, the IDFP induced decreased uptake of plasma
lipoproteins may transiently decrease hepatic cholesterol content,
triggering SREBP2 activity. Although we did not detect alterations
in hepatic cholesterol content, the small magnitude and transience
of changes required to stimulate SREBP2 processing may not be
detectable by the present methodology.
There is a complex relationship between CB1 signaling and
inflammation. Both activation and inhibition of CB1 have been
shown to have anti-inflammatory outcomes in different contexts
[46,47,48,49]. In our study, IDFP decreased expression of genes
encoding acute phase proteins in a CB1-dependent manner.
Interestingly, stat3 and several of its targets (apcs, lbp) were
downregulated in livers of IDFP-treated mice. In neurons CB1
activation stimulates stat3 [50]. Consistent with a reversal of this
system in the liver, rimonabant administration was shown to
potentiate stat3 activation in response to lipopolysaccharide
stimulation [46]. While our results establish that CB1 stimulation
limits hepatic inflammation at the mRNA level under basal
conditions, the role of CB1 on systemic inflammation in response
to various stimuli remains to be determined.
Inflammatory signaling pathways, including stat3, influence
metabolic regulation. STAT3 signaling mediates the hypophagic
Figure 6. CB1-dependent effects of IDFP on hepatic expression
of genes involved in lipid metabolism (A), inflammation (B),
and amino acid metabolism (C). RNA was isolated from the mice
used for the experiment in Fig. 2. n=16–18. Groups not sharing a
common superscript letter are significantly different (p,0.05).
doi:10.1371/journal.pone.0026415.g006
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regulates srebp1c which was increased by IDFP in a CB1-
dependent manner [51,52]. Hepatocyte specific loss of stat3
produces insulin resistance and increases susceptibility to ethanol
induced hepatic steatosis, lipogenic gene expression, and hyper-
triglyceridemia [51,53]. Findings with a non-brain-penetrant CB1
antagonist suggest that diet-induced leptin resistance may result
from overactive peripheral CB1 signaling [22]. The current study
raises the possibility that CB1 mediated inhibition of hepatic
STAT3 signaling may influence leptin sensitivity.
LCN2 is an acute phase protein known to regulate energy and
glucose metabolism [54,55]. Although LCN2 is a member of the
lipocalin sub-family of secreted proteins that bind hydrophobic
molecules, its specific ligands remain largely unknown [56]. Lcn2
knockout animals are cold intolerant and more susceptible to diet-
induced increases in plasma lipids and adipose mass [55,57]. Reports
on insulin sensitivity and hepatic lipid content in lcn2 deficient mice
are discordant with one group reporting protective and another
potentiating effects [55,57]. In our study, IDFP inhibited expression
of hepatic lcn2. Interestingly, AM251 pre-administration not only
prevented the effects of IDFP, but also increased lcn2 expression
compared to controls. This suggests that tonic endogenous CB1
stimulation may limit lcn2 expression. EC binding to lipocalins has
been suggested to facilitate their release from the plasma membrane
and subsequent delivery to targets [58]. If this is the case, the robust
regulation of lcn2 by CB1 observed here may represent a feedback
cycle. Alternatively, we cannot exclude the possibility that this effect
could be independent of ECs and may reflect the inverse agonist
properties of AM251. Future studies will be necessary to clarify the
relationship between lcn2 and CB1 signaling.
Although CB1 signaling has been linked to ER stress and
mammalian target of rapamycin (mTOR) activity, the relationship
between ECs and amino acid metabolism remains unclear.
mTOR is a serine/threonine protein kinase central to regulation
of amino acid metabolism and translation. THC, in a CB1-
dependent fashion, stimulates mTOR in the hippocampus, but
inhibits mTOR by stimulating ER stress in cancer cells [59,60].
Recently, administration of a non-brain-penetrant CB1 antagonist
has been found to reverse ER stress caused by a high fat diet [22].
In our study of hepatic tissue gene expression, IDFP caused a
CB1-dependent decrease in the gene cassette involved in
translation and amino acid metabolism.
As IDFP inhibits both FAAH and MAGL, the CB1-dependent
effects cannot be specifically ascribed to increases in either AEA or
2-AG levels. Animals deficient in FAAH, with elevated AEA but
not 2-AG, have increased body weight, tissue TG content, fasting
blood glucose and insulin compared to controls when fed a high fat
diet, without differences in food intake [61]. The use of specific
chemical inhibitors or genetic manipulation of MAGL and/or
FAAH will be necessary to establish the relative contribution of
each enzyme to the effects shown here. The simultaneous
elevation of AEA and 2-AG has been shown to have synergistic
effects that are not recapitulated by raising levels of either EC
alone [34]. Moreover, synthetic CB1 agonists may bind the
receptor differently and produce differential downstream respons-
es than the ECs. Nevertheless, study of the effects of synthetic CB1
agonists on expression of the genes found here to be responsive to
IDFP, and the reversal of these effects by AM251, would be
informative.
IDFP is perhaps the most potent dual FAAH/MAGL inhibitor
reported to date and although it does not reduce AChE activity
there could be other off target effects that may potentiate the
IDFP-induced metabolic effects observed in this study [25,27]
(Supplemental Table S7). The carbamate FAAH/MAGL inhib-
itor JZL195 displays better specificity in the brain, but its
selectivity in other tissues has not yet been established [54]. It is
likely to have additional off-targets similar to those of the
structurally-related MAGL-selective inhibitor JZL184 [62]. Our
previous studies have shown that AM251 completely reverses all
cannabinoid-mediated behavioral effects observed with IDFP or
direct CB1 agonists such as WIN55212-2 [25]. We have therefore
restricted our interpretations to the IDFP-effects that are reversible
with cannabinoid receptor antagonism.
While the current study addresses the acute metabolic effects of
dual MAGL/FAAH inhibition, the chronic metabolic effects of
such inhibition requires further investigation. Genetic ablation of
FAAH promotes increases in body weight, adipose tissue amount,
plasma free fatty acids and triglyceride content in plasma, liver,
skeletal muscle, and adipose tissue [61]. On the other hand, as
MAGL deficient mice have reduced sensitivity to CB1 agonists
and attenuated diet-induced insulin resistance, chronic elevation of
2-AG may lead to functional antagonism of cannabinoid receptors
potentially negating the effects of elevations in 2-AG [33,63].
In summary, our results support a causative role of CB1
signaling in the development of hepatic steatosis and insulin
resistance. Furthermore, we have identified novel genes responsive
to IDFP in a CB1-dependent manner that may guide future
research on CB1-mediated modulation of pathways impacting
lipid and glucose metabolism.
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Figure S1 CB1-dependent effects of IDFP on hepatic TG
(A) and cholesterol (B) levels. Wild-type and CB1 2/2 mice
were treated with DMSO or IDFP (10 mg/kg, ip, 4 h). n=5–6.
Significance is given as *p,0.05.
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Figure S2 IDFP causes CB1-dependent and-indepen-
dent glucose intolerance. Wild-type (A) and CB1 2/2 (B) mice
were treated with DMSO or IDFP (10 mg/kg, ip, 4 h). Two h following
DMSO or IDFP treatment, mice were administered glucose (2 g/kg)
and plasma glucose determined at the time points indicated. n=5.
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Table S1 PCR Primers Sequence of primers used to amplify
transcripts in PCR.
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details of one- and two-way ANOVAs used to determine
significance.
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Table S4 Panther Biological Process Analysis Biological
processes found to be significantly altered by Panther analysis.
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Table S5 FuncAssociate 2.0 Analysis of Genes De-
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of FuncAssocaite analysis of genes (n=168) downregulated by
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Table S6 Expression of Genes involved in Stat3 signal-
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Wild-type and CB1 2/2 mice were treated with DMSO or IDFP
Metabolic and Genetic Responses to CB1 Activation
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e26415(10 mg/kg, ip, 4 h). Groups not sharing a common superscript
letter are significantly different (p,0.05). n=5.
(DOCX)
Table S7 Known off target effects of IDFP Enzymes known
to be altered by IDFP.
(DOCX)
Author Contributions
Conceived and designed the experiments: MAR DKN JEC RMK.
Performed the experiments: MAR DKN CSSH AB. Analyzed the data:
MAR DKN JEC RMK. Wrote the paper: MAR DKN JEC RMK.
References
1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al.
(2002) The metabolic syndrome and total and cardiovascular disease mortality in
middle-aged men. Jama 288: 2709–2716.
2. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, et al. (2006)
Dysregulation of the peripheral and adipose tissue endocannabinoid system in
human abdominal obesity. Diabetes 55: 3053–3060.
3. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, et al. (2005)
Activation of the peripheral endocannabinoid system in human obesity. Diabetes
54: 2838–2843.
4. Sipe JC, Waalen J, Gerber A, Beutler E (2005) Overweight and obesity
associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).
Int J Obes (Lond) 29: 755–759.
5. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, et al. (2008)
Dysregulation of peripheral endocannabinoid levels in hyperglycemia and
obesity: Effect of high fat diets. Mol Cell Endocrinol 286: S66–78.
6. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, et al. (2009) Peripheral
endocannabinoid dysregulation in obesity: relation to intestinal motility and
energy processing induced by food deprivation and re-feeding. Br J Pharmacol
158: 451–461.
7 .D iM a r z oV ,C o t eM ,M a t i a sI ,L e m i e u xI ,A r s e n a u l tB J ,e ta l .( 2 0 0 9 )
Changes in plasma endocannabinoid levels in viscerally obese men following
a 1 year lifestyle modification programme and waist circumference reduction:
associations with changes in metabolic risk factors. Diabetologia 52:
213–217.
8. Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk
factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121–2134.
9. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of
rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic
risk factors in overweight or obese patients: RIO-North America: a randomized
controlled trial. Jama 295: 761–775.
10. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF (2006) Efficacy and
tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a
randomised controlled study. Lancet 368: 1660–1672.
11. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S (2005) Effects of
the cannabinoid-1 receptor blocker rimonabant on weight reduction and
cardiovascular risk factors in overweight patients: 1-year experience from the
RIO-Europe study. Lancet 365: 1389–1397.
12. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, et al. (2008)
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk
factors: two year results from the RIO-Europe Study. Eur Heart J 29:
1761–1771.
13. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, et al. (1998) Appetite
suppression and weight loss after the cannabinoid antagonist SR 141716. Life
Sci 63: PL113–117.
14. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, et al. (2003) The
endogenous cannabinoid system affects energy balance via central orexigenic
drive and peripheral lipogenesis. J Clin Invest 112: 423–431.
15. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, et al. (2001) Leptin-
regulated endocannabinoids are involved in maintaining food intake. Nature
410: 822–825.
16. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, et al. (2005) The
CB1 receptor antagonist rimonabant reverses the diet-induced obesity
phenotype through the regulation of lipolysis and energy balance. Faseb J 19:
1567–1569.
17. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, et al. (2003)
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced
obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345–353.
18. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P (2004) CB1
cannabinoid receptor knockout in mice leads to leanness, resistance to diet-
induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord
28: 640–648.
19. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, et al. (2005)
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid
synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298–1305.
20. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, et al. (2008) Paracrine
activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids
mediates alcoholic fatty liver. Cell Metab 7: 227–235.
21. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, et al. (2008)
Hepatic CB1 receptor is required for development of diet-induced steatosis,
dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:
3160–3169.
22. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, et al. (2010) Peripheral
CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse
models of obesity. J Clin Invest 120: 2953–2966.
23. Ahn K, McKinney MK, Cravatt BF (2008) Enzymatic pathways that regulate
endocannabinoid signaling in the nervous system. Chem Rev 108: 1687–1707.
24. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, et al. (1994)
The pharmacological activity of anandamide, a putative endogenous cannabi-
noid, in mice. J Pharmacol Exp Ther 270: 219–227.
25. Nomura DK, Blankman JL, Simon GM, Fujioka K, Issa RS, et al. (2008)
Activation of the endocannabinoid system by organophosphorus nerve agents.
Nat Chem Biol 4: 373–378.
26. Ruby MA, Nomura DK, Hudak CS, Mangravite LM, Chiu S, et al. (2008)
Overactive endocannabinoid signaling impairs apolipoprotein E-mediated
clearance of triglyceride-rich lipoproteins. Proc Natl Acad Sci U S A 105:
14561–14566.
27. Segall Y, Quistad GB, Sparks SE, Nomura DK, Casida JE (2003) Toxicological
and structural features of organophosphorus and organosulfur cannabinoid CB1
receptor ligands. Toxicol Sci 76: 131–137.
28. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999)
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor
knockout mice. Proc Natl Acad Sci U S A 96: 5780–5785.
2 9 .D eG o t t a r d iA ,S p a h rL ,R a v i e r - D a l l ’ A n t o n i aF ,H a d e n g u eA( 2 0 1 0 )
Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in
hepatocytes. Liver Int 30: 1482–1489.
30. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, et al. (2005)
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid
synthesis and contributes to diet-induced obesity. Journal of Clinical Investiga-
tion 115: 1298–1305.
31. Alonzi T, Maritano D, Gorgoni B, Rizzuto G, Libert C, et al. (2001) Essential
role of STAT3 in the control of the acute-phase response as revealed by
inducible gene inactivation [correction of activation] in the liver. Mol Cell Biol
21: 1621–1632.
32. Buettner C, Muse ED, Cheng A, Chen L, Scherer T, et al. (2008) Leptin
controls adipose tissue lipogenesis via central, STAT3-independent mechanisms.
Nat Med 14: 667–675.
33. Taschler U, Radner FP, Heier C, Schreiber R, Schweiger M, et al. (2011)
Monoglyceride lipase-deficiency in mice impairs lipolysis and attenuates diet-
induced insulin resistance. J Biol Chem.
34. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, et al. (2009) Dual
blockade of FAAH and MAGL identifies behavioral processes regulated by
endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A 106:
20270–20275.
35. Long JZ, LaCava M, Jin X, Cravatt BF (2011) An anatomical and temporal
portrait of physiological substrates for fatty acid amide hydrolase. J Lipid Res 52:
337–344.
36. Hollister LE, Reaven GM (1974) Delta-9-tetrahydrocannabinol and glucose
tolerance. Clin Pharmacol Ther 16: 297–302.
37. Liu YL, Connoley IP, Wilson CA, Stock MJ (2005) Effects of the cannabinoid
CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle
glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29: 183–187.
38. Ueyama J, Kamijima M, Asai K, Mochizuki A, Wang D, et al. (2008) Effect of
the organophosphorus pesticide diazinon on glucose tolerance in type 2 diabetic
rats. Toxicol Lett 182: 42–47.
39. Zadik Z, Blachar Y, Barak Y, Levin S (1983) Organophosphate poisoning
presenting as diabetic ketoacidosis. J Toxicol Clin Toxicol 20: 381–385.
40. Shobha TR, Prakash O (2000) Glycosuria in organophosphate and carbamate
poisoning. J Assoc Physicians India 48: 1197–1199.
41. Meller D, Fraser I, Kryger M (1981) Hyperglycemia in anticholinesterase
poisoning. Can Med Assoc J 124: 745–748.
42. Seifert J (2001) Toxicologic significance of the hyperglycemia caused by
organophosphorous insecticides. Bull Environ Contam Toxicol 67: 463–469.
43. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, et al. (2005) Hyperlipidemic
effects of dietary saturated fats mediated through PGC-1beta coactivation of
SREBP. Cell 120: 261–273.
44. Li LO, Ellis JM, Paich HA, Wang S, Gong N, et al. (2009) Liver-specific loss of
long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-
oxidation and alters phospholipid fatty acid composition. J Biol Chem 284:
27816–27826.
45. Li LO, Mashek DG, An J, Doughman SD, Newgard CB, et al. (2006)
Overexpression of rat long chain acyl-coa synthetase 1 alters fatty acid
metabolism in rat primary hepatocytes. J Biol Chem 281: 37246–37255.
Metabolic and Genetic Responses to CB1 Activation
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e2641546. Caraceni P, Pertosa AM, Giannone F, Domenicali M, Grattagliano I, et al.
(2009) Antagonism of the cannabinoid CB-1 receptor protects rat liver against
ischaemia-reperfusion injury complicated by endotoxaemia. Gut 58: 1135–1143.
47. Croci T, Landi M, Galzin AM, Marini P (2003) Role of cannabinoid CB1
receptors and tumor necrosis factor-alpha in the gut and systemic anti-
inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol
140: 115–122.
48. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, et al. (2004) The
endogenous cannabinoid system protects against colonic inflammation. J Clin
Invest 113: 1202–1209.
49. Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce
hyperalgesia and inflammation via interaction with peripheral CB1 receptors.
Pain 75: 111–119.
50. He JC, Gomes I, Nguyen T, Jayaram G, Ram PT, et al. (2005) The G alpha(o/
i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap
regulation of Src and Stat3. J Biol Chem 280: 33426–33434.
51. Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, et al. (2004) Role of
STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate
metabolism in vivo. Nat Med 10: 168–174.
52. Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of
cytokine signaling proteins in hepatic steatosis, insulin resistance, and the
metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 101: 10422–10427.
53. Horiguchi N, Wang L, Mukhopadhyay P, Park O, Jeong WI, et al. (2008) Cell
type-dependent pro- and anti-inflammatory role of signal transducer and
activator of transcription 3 in alcoholic liver injury. Gastroenterology 134:
1148–1158.
54. Liu Q, Nilsen-Hamilton M (1995) Identification of a new acute phase protein.
J Biol Chem 270: 22565–22570.
55. Guo H, Jin D, Zhang Y, Wright W, Bazuine M, et al. (2010) Lipocalin-2
deficiency impairs thermogenesis and potentiates diet-induced insulin resistance
in mice. Diabetes 59: 1376–1385.
56. Flower DR, North AC, Sansom CE (2000) The lipocalin protein family:
structural and sequence overview. Biochim Biophys Acta 1482: 9–24.
57. Law IK, Xu A, Lam KS, Berger T, Mak TW, et al. (2010) Lipocalin-2 deficiency
attenuates insulin resistance associated with aging and obesity. Diabetes 59:
872–882.
58. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev
Neurosci 4: 873–884.
59. Salazar M, Carracedo A, Salanueva IJ, Hernandez-Tiedra S, Lorente M, et al.
(2009) Cannabinoid action induces autophagy-mediated cell death through
stimulation of ER stress in human glioma cells. J Clin Invest 119: 1359–1372.
60. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, et al.
(2009) Cannabinoid modulation of hippocampal long-term memory is mediated
by mTOR signaling. Nat Neurosci 12: 1152–1158.
61. Tourino C, Oveisi F, Lockney J, Piomelli D, Maldonado R (2010) FAAH
deficiency promotes energy storage and enhances the motivation for food.
Int J Obes (Lond) 34: 557–568.
62. Long JZ, Nomura DK, Cravatt BF (2009) Characterization of monoacylglycerol
lipase inhibition reveals differences in central and peripheral endocannabinoid
metabolism. Chem Biol 16: 744–753.
63. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, et al. (2010)
Chronic monoacylglycerol lipase blockade causes functional antagonism of the
endocannabinoid system. Nat Neurosci 13: 1113–1119.
Metabolic and Genetic Responses to CB1 Activation
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e26415